Table 1.
Summary of included studies and readmission rates
| Inclusion outpatients | Treatment | |||||||
|---|---|---|---|---|---|---|---|---|
| Study | Study design | Abscess | Comor-bidity | Left-sided | Antibiotics | First follow-up after | Readmission outpatient |
Readmission inpatient |
| Alonso 201018 | Pros | No | No | 100% | Yes | 4–7 days | 3% (2/70) | – |
| Biondo 201417 | RCT | No | No | 100% | Yes | Daily | 4.5% (3/66) | 6.1% (4/66) |
| Estrada 201619 | Pros | No | No | 100% | No | 48 h | 11.1% (4/36) | 33.3% (3/9) |
| Etzioni 201028 | Retro | Yes | NR | NR | NR | NR | 5.6% (39/693) | – |
| Isacson 201520 | Pros | No | No | 100% | No | 1 week | 2.3% (4/155) | – |
| Joliat 201729 | Retro | Yes | Yes | 96% | Yes | NR | 10.2% (10/98) | 32.0% (54/169) |
| Lorente 201330 | Retro | No | No | NR | Yes | 4–7 days | 5.6% (5/90) | 4.3% (2/46) |
| Lutwak 201232 | Retro | No | No | NR | Yes | NR | 14.3% (3/21) | 0.0% (0/21) |
| Mali 201621 | Pros | No | No | 94% | No | 24-48 h | 2.9% (4/140) | – |
| Martin Gil 200922 | Pros | Yes | No | NR | Yes | 10 days | 5.4% (4/74) | – |
| Mora 201723 | Pros | No | No | NR | Yes | 2 weeks | 8.7% (22/254) | – |
| Moya 201224 | Pros | No | No | 84% | Yes | 4 days | 6.3% (2/32) | 0.0% (0/44) |
| Moya 201631 | Retro | Yes | No | 95% | Yes | 4 days | 8.0% (18/224) | – |
| Pelaez 200625 | Pros | No | No | 100% | Yes | 4 days | 5.0% (2/40) | – |
| Rodriguez 201027 | Pros | No | Yes | NR | Yes | Daily | 0.0% (0/24) | – |
| Rodriguez 201326 | Pros | No | Yes | NR | Yes | Daily | 0.0% (0/34) | – |
| Rueda 201233 | Retro | Yes | No | NR | Yes | NR | 21.1% (8/38) | 27.8% (5/18) |
| Sirany 201734 | Retro | Yes | Yes | 96% | Yes | NR | 12.5% (12/96) | 15.3% (22/144) |
| Ünlü 201335 | Retro | Yes | Yes | 100% | Somea | 1 week | 8.5% (10/118) | – |
Pros, prospective cohort study; Retro, retrospective cohort study; RCT, randomized controlled trial; NR, not reported
a7 (6%) of 118 patients were treated with antibiotics